Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China

被引:5
作者
Hao, Sida [1 ]
Wang, Hao [1 ]
Lin, Shen [1 ]
Chen, Hong [1 ]
Xie, Liping [1 ]
Zheng, Xiangyi [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China
关键词
Prostate cancer; PSA persistence; Radical prostatectomy; Risk factors; PREDICTIVE FACTORS; ANTIGEN; CANCER; RADIOTHERAPY; SURVIVAL;
D O I
10.1186/s12894-024-01563-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background For localized prostate cancer, a comprehensive treatment approach centered around radical prostatectomy (RP) is often their optimal choice. Successful RP can typically reduce prostate-specific antigen (PSA) levels to below 0.1 ng/mL within 6 to 8 weeks postoperatively. However, in clinical practice, 5 to 24% of patients may have a PSA >= 0.1 ng/mL at 6 to 8 weeks after surgery, a phenomenon known as PSA persistence. Many studies based on data from Europe and United States have shown an association between PSA persistence and poor postoperative outcomes, further analyzing the risk factors for PSA persistence. However, relevant research based on data from China remains scarce. Methods Retrospective study of 1,347 prostate cancer patients who underwent RP at the First Affiliated Hospital of Zhejiang University School of Medicine from July 15, 2016, to August 31, 2022. Based on inclusion criteria, univariate and multivariate logistic regression analyses were conducted to explore the independent risk factors for persistent PSA. Results Among the 826 prostate cancer patients after RP, 124 patients experienced persistent PSA. In univariate logistic regression analysis, robot-assisted laparoscopic radical prostatectomy (RARP), preoperative PSA, high-risk group, preoperative International Society of Urological Pathology (ISUP) grades 2-5, postoperative ISUP grades 3-5, percentage of positive cores, cT3, >= pT3b, extracapsular extension (EPE), seminal vesicle invasion (SVI), positive surgical margins (PSM) and Prostate Specific Antigen Density (PSAD) were all significantly associated with PSA persistence after RP (P < 0.05). In terms of surgical approach, RARP was considered a protective factor against postoperative PSA persistence (OR:0.53, p < 0.05). In multivariate logistic regression analysis, preoperative ISUP grade 4, percentage of positive cores and PSM were independent risk factors of PSA persistence after RP (P < 0.05). Conclusion Preoperative PSA, high-risk group, preoperative ISUP grades 2-5, postoperative ISUP grades 3-5, percentage of positive cores, cT3, >= pT3b, EPE, SVI, PSM and PSAD were independent risk factors for PSA persistence in prostate cancer patients after RP. This provides assistance for early monitoring and treatment of patients at high risk of persistent PSA in clinical practice.
引用
收藏
页数:12
相关论文
共 24 条
[1]   The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients [J].
Bianchi, Lorenzo ;
Nini, Alessandro ;
Bianchi, Marco ;
Gandaglia, Giorgio ;
Fossati, Nicola ;
Suardi, Nazareno ;
Moschini, Marco ;
Dell'Oglio, Paolo ;
Schiavina, Riccardo ;
Montorsi, Francesco ;
Briganti, Alberto .
EUROPEAN UROLOGY, 2016, 69 (06) :1142-1148
[2]   The learning curves of major laparoscopic and robotic procedures in urology: a systematic review [J].
Chahal, Baldev ;
Aydin, Abdullatif ;
Amin, Mohammad S. A. ;
Khan, Azhar ;
Khan, Muhammad S. ;
Ahmed, Kamran ;
Dasgupta, Prokar .
INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (07) :2037-2057
[3]   Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up [J].
Eastham, James A. ;
Auffenberg, Gregory B. ;
Barocas, Daniel A. ;
Chou, Roger ;
Crispino, Tony ;
Davis, John W. ;
Eggener, Scott ;
Horwitz, Eric M. ;
Kane, Christopher J. ;
Kirkby, Erin ;
Lin, Daniel W. ;
McBride, Sean M. ;
Morgans, Alicia K. ;
Pierorazio, Phillip M. ;
Rodrigues, George ;
Wong, William W. ;
Boorjian, Stephen A. .
JOURNAL OF UROLOGY, 2022, 208 (01) :19-25
[4]   Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis [J].
Gandaglia, Giorgio ;
Boorjian, Stephen A. ;
Parker, William P. ;
Zaffuto, Emanuele ;
Fossati, Nicola ;
Bandini, Marco ;
Dell'Oglio, Paolo ;
Suardi, Nazareno ;
Montorsi, Francesco ;
Karnes, R. Jeffrey ;
Briganti, Alberto .
EUROPEAN UROLOGY, 2017, 72 (06) :910-917
[5]   Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy [J].
Garcia-Barreras, S. ;
Rozet, F. ;
Nunes-Silva, I. ;
Srougi, V. ;
Sanchez-Salas, R. ;
Barret, E. ;
Galiano, M. ;
Cathelineau, X. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (08) :1004-1010
[6]   Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients [J].
Kim, Jung Kwon ;
Jeong, Chang Wook ;
Ku, Ja Hyeon ;
Kim, Hyun Hoe ;
Kwak, Cheol .
JOURNAL OF CANCER, 2019, 10 (10) :2237-2242
[7]   Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis [J].
Kimura, Shoji ;
Urabe, Fumihiko ;
Sasaki, Hiroshi ;
Kimura, Takahiro ;
Miki, Kenta ;
Egawa, Shin .
CANCERS, 2021, 13 (05) :1-11
[8]   Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade [J].
McKay, Rana R. ;
Montgomery, Bruce ;
Xie, Wanling ;
Zhang, Zhenwei ;
Bubley, Glenn J. ;
Lin, David W. ;
Preston, Mark A. ;
Quoc-Dien Trinh ;
Chang, Peter ;
Wagner, Andrew A. ;
Mostaghel, Elahe A. ;
Kantoff, Philip W. ;
Nelson, Peter S. ;
Kibel, Adam S. ;
Taplin, Mary-Ellen .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (03) :364-372
[9]   Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy [J].
Milonas, D. ;
Laenen, A. ;
Venclovas, Z. ;
Jarusevicius, L. ;
Devos, G. ;
Joniau, S. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (02) :371-378
[10]   The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes [J].
Milonas, Daimantas ;
Venclovas, Zilvinas ;
Sasnauskas, Gustas ;
Ruzgas, Tomas .
CANCERS, 2021, 13 (10)